行情

PTN

PTN

Palatin科技
AMEX

实时行情|Nasdaq Last Sale

0.7820
-0.0380
-4.63%
盘前: 0.8100 +0.028 +3.58% 09:06 03/01 EST
开盘
0.7994
昨收
0.8200
最高
0.8189
最低
0.7640
成交量
10.20万
成交额
--
52周最高
1.300
52周最低
0.3550
市值
1.80亿
市盈率(TTM)
-6.9326
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
Melanocortin Receptor 4市场发展，市场趋势，关键驱动因素，细分和预测2020-2027通过Ameco Research
pune, India, Mon, 22 Feb 2021 01:39:22 / Comserve Inc. / -- Melanocortin Receptor 4 market is segmented by Type, and by Application. Players, stakeholders,...
Comserve · 02/22 06:40
Palatin Technologies（PTN）连续第三次购买
SmarterAnalyst · 02/18 11:46
HC Wainwright维持对Palatin Technologies（PTN）的买入评级
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Palatin Technologies (PTN) today and set a price target of $2.00. The company's shares
SmarterAnalyst · 02/18 11:18
Palatin Technologies（PTN）收到Canaccord Genuity的收购
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Palatin Technologies (PTN), with a price target of $3.00.
SmarterAnalyst · 02/18 11:07
2021年黑皮质素受体4市场：COVID-19的影响，随着现代趋势，发展，规模，份额，收入，需求和到2027年的预测而迅速增长
Feb 18, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Melanocortin Receptor 4...
The Express Wire · 02/18 05:22
8-K：PALATIN TECHNOLOGIES INC
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/17 14:11
Palatin Technologies第二季度每股收益（$ 0.04）未达到预期的（$ 0.01）
Palatin Technologies (AMEX:PTN) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 300 percent. This is a 100 percent decrease over losses of $(0.02) per share from
Benzinga · 02/17 12:31
一份新报告解释说，到2027年，LATAM性欲减退（HSDD）治疗市场规模预计将实现蓬勃发展
Feb 17, 2021 (Market Insight Reports) -- The LATAM women hypoactive sexual desire disorder treatment market accounted for $967 million in 2019, and is...
Market Insight Reports · 02/17 11:14
更多
财务预测
每股收益每股净资产每股现金流
实际值（美元）
预测值（美元）
利润表更多
净利润营业总收入营业利润
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流（美元）
同比（%）
了解PTN最新的财务预测，通过PTN每股收益，每股净资产，每股现金流等数据分析Palatin科技近期的经营情况，然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

强力推荐

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测PTN价格均价为2.333，最高价位3.000，最低价为2.000。
EPS
机构持股
总机构数: 98
机构持股: 4,469.12万
持股比例: 19.43%
总股本: 2.30亿
类型机构数股数
增持
32
480.92万
建仓
20
135.83万
减持
17
134.26万
平仓
6
112.48万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.06%
制药与医学研究
-0.68%
高管信息
Chairman/Independent Director
John Prendergast
President/Chief Executive Officer/Director
Carl Spana
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
Stephen Wills
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
stephen Wills
Independent Director
Robert deVeer
Independent Director
Alan Dunton
Independent Director
Joseph Hull
Independent Director
Anthony Manning
Independent Director
Arlene Morris
  • 分红
  • 拆股
  • 内部人交易
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
PTN 简况
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.

微牛提供Palatin Technologies, Inc.(AMEX-PTN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PTN股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PTN股票基本功能。